Active substance
Valganciclovir
- SFDA 6
- US FDA 20
- Health Canada 6
- US price lines 2
- NHS prices 2
- WHO EML 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| VALCYTE 450MG FILM - COATED TABLETS | 450 mg | Film-coated tablet · Oral use | 60 Blister | SAR 3791.75 | NCE · Prescription | CHEPLAPHARM Arzneimittel GmbH | Valid |
| VALGAN | 450 mg | Film-coated tablet · Oral use | 60 Blister | SAR 2499.85 | Generic · Prescription | Saudi Amarox | Valid |
| VALGAN 50MG/ML POWDER FOR ORAL SOLUTION | 50 mg/ml | Powder for oral solution · Oral use | 1 Bottle | SAR 1270.50 | Generic · Prescription | Saudi Amarox | Valid |
| VERCANZA 450 MG FILM COATED TABLET | 450 mg | Film-coated tablet · Oral use | 60 Bottle | SAR 3686.50 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| Valgaset | 450 mg | Tablet · Oral use | 60 Blister | SAR 2499.85 | Generic · Prescription | ALTAIF PHARMACEUTICALS COMPANY | Valid |
| Valgiver | 450 mg | Film-coated tablet · Oral use | 60 Bottle | SAR 2499.85 | Generic · Prescription | ADEL AHMED AL-SHAEIR PHARMACEUTICAL COMPANY | Valid |
Indications — CHI Daman Drug Formulary
CASTLEMAN DISEASE; HERPESVIRAL KERATITIS,ZOSTER KERATITIS, KERATITIS,OTHER CYTOMEGALOVIRAL DISEASES; HUMAN IMMUNODEFICIENCY VIRUS; RENAL TRANSPLANT; VIRAL GASTROENTERITIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VALCYTE | 50MG/ML | for solution · oral | CHEPLAPHARM | Prescription | 28 Aug 2009 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | STRIDES PHARMA INTL | Prescription | 4 Nov 2014 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | DR REDDYS | Prescription | 4 Nov 2014 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | HETERO LABS LTD V | Prescription | 18 Mar 2016 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 31 Mar 2016 |
| VALGANCICLOVIR HYDROCHLORIDE | 50MG/ML | for solution · oral | ACTAVIS LABS FL INC | Prescription | 18 Jul 2016 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | DR REDDYS | Prescription | 12 Dec 2017 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | AJANTA PHARMA LTD | Prescription | 26 Dec 2019 |
| VALGANCICLOVIR HYDROCHLORIDE | 50MG/ML | for solution · oral | AJANTA PHARMA LTD | Prescription | 13 Jan 2020 |
| VALGANCICLOVIR HYDROCHLORIDE | 50MG/ML | for solution · oral | GRANULES | Prescription | 31 Jan 2020 |
| VALGANCICLOVIR HYDROCHLORIDE | 50MG/ML | for solution · oral | MSN | Prescription | 17 Feb 2022 |
| VALGANCICLOVIR HYDROCHLORIDE | 50MG/ML | for solution · oral | HETERO LABS LTD V | Prescription | 4 Oct 2022 |
| VALGANCICLOVIR HYDROCHLORIDE | 50MG/ML | for solution · oral | AUROBINDO PHARMA | Prescription | 17 Nov 2022 |
| VALGANCICLOVIR HYDROCHLORIDE | 50MG/ML | for solution · oral | APPCO | Prescription | 11 Apr 2023 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | SOMERSET THERAPS LLC | Prescription | 11 Jun 2024 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | SPH ZHONGXI PHARM | Prescription | 16 Apr 2025 |
| VALGANCICLOVIR HYDROCHLORIDE | 50MG/ML | for solution · oral | MICRO LABS | Prescription | 19 Mar 2026 |
| VALCYTE | EQ 450MG BASE | tablet · oral | CHEPLAPHARM | Discontinued | 29 Mar 2001 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | CIPLA | Discontinued | 9 Nov 2018 |
| VALGANCICLOVIR HYDROCHLORIDE | EQ 450MG BASE | tablet · oral | PHARMOBEDIENT | Discontinued | 3 Mar 2021 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-VALGANCICLOVIR | 02435179 | 450 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-VALGANCICLOVIR | 02535483 | 50 MG / ML | POWDER FOR SOLUTION · ORAL | AURO PHARMA INC |
| MINT-VALGANCICLOVIR | 02495457 | 450 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| TEVA-VALGANCICLOVIR | 02413825 | 450 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| VALCYTE | 02245777 | 450 MG | TABLET · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
| VALCYTE | 02306085 | 50 MG / ML | POWDER FOR SOLUTION · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | VALGANCICLOVIR 450 MG TABLET | $1.91499 | per EA | 23 Sep 2026 |
| US NADAC | VALGANCICLOVIR HCL 50 MG/ML | $1.00585 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Valganciclovir 450mg tablets | £1081.46 | 60 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Valganciclovir 50mg/ml oral solution sugar free | £230.32 | 88 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.4.3. Other antivirals · core (EML); complementary (EMLc)
Cytomegaloviral retinitis
Oral > Liquid: 50 mg per mL (as hydrochloride) powder for oral solution (EMLc) | Oral > Solid > tablet: 450 mg (as hydrochloride)
Safety signals and safety-related labeling changes
- US FDA 2 Aug 2018 VALCYTE — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 2 Aug 2018 VALCYTE — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.